App-Quantinova.ai

Analysis of prognostic factors in childhood advanced stage Hodgkin lymphoma: A retrospective study.

Amol Shankar Dongre - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

N/A

Sensitivity and specificity of an oral uracil-loading test dose for screening for DPD deficiency.

M C van Staveren - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Dihydropyrimidine dehydrogenase deficiency

Adrucil injection

Circulating tumor cells (CTC) as potential biomarkers in neoadjuvant chemotherapy of muscle invasive bladder cancer (MIBC).

Ajjai Shivaram Alva - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

Programmed death-ligand 1 characterization of circulating tumor cells and white blood cells in muscle-invasive and metastatic bladder cancer patients.

Terence W. Friedlander - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

Modeling breast cancer metastasis in the mouse via measurement of circulating tumor cells

Gorman JL - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

The Usefulness of Ultra-low Dose CT colonography for Assessing Mucosal Inflammation in Patients with Ulcerative Colitis

K. Takeuchi - European Crohn’s and Colitis Organisation (ECCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

Phase I and dose ranging, phase II studies with IPH2201, a humanized monoclonal antibody targeting HLA-E receptor CD94/NKG2A

L. Seymour - International Congress on Targeted Anticancer Therapies (TAT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Pembrolizumab

The clinical potential of ARGX-111, an afucosylated anti-MET antibody, in hematological malignancies and suppression of metastasis

V. Hanssens - International Congress on Targeted Anticancer Therapies (TAT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hematological malignancies

ARGX-111

DNA methylation in serum as an independent marker of outcome and treatment response in TBCRC 005: A prospective study in metastatic breast cancer (MBC) patients.

Kala Visvanathan - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

HLA-DRB1*07:01 biomarker characterization of hepatotoxicity during lapatinib combination therapies in ALTTO.

Colin F. Spraggs - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

N/A

Lapatinib

A novel approach to assess Her2-status of circulating tumour cells (CTCs) using the automated BioMarQ System.

Elisabeth Katharina Trapp - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Effectiveness of targeting HER2 in heavily pretreated patients with occult HER2-positive (tissue-negative, serum-positive and/or HER2-positive circulating tumor cells) metastatic breast cancer in the clinical routine.

Christian M. Kurbacher - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.

Nadia Harbeck - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

Phase III trial of etirinotecan pegol (EP) versus Treatment of Physicians Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study.

Edith A. Perez - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Brain metastasis

etirinotecan pegol

Randomized phase II trial to evaluate the safety and efficacy of neoadjuvant cisplatin in combination with taxanes-anthracyclines vs taxanes-anthracyclines alone in locally advanced triple negative breast cancer.

Maria Cristina Aguilar Martinez - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Cyclophosphamide

NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer.

Steven J. Chmura - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Prospective validation of cerebrospinal fluid (CSF) circulating tumor cells (CTC) to diagnose leptomeningeal metastasis (LM) from epithelial tumors.

Xuling Lin - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Leptomeningeal Metastasis

N/A

A randomized Phase 2a study to assess pharmacodynamics, antitumor activity and safety of intravenous BAL101553, a novel microtubule inhibitor, at two dose levels in adult patients with selected advanced solid tumors.

Rebecca Sophie Kristeleit - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

BAL-101553

SORAVE: A phase I trial to evaluate safety and efficacy of combination therapy with everolimus and sorafenib.

Christian Mattonet - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Everolimus

Glioma circulating tumor cells trends and molecular characterization

Mariana Cooke - Society for Neuro-Oncology (SNO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

High-Grade Gliomas

N/A

Filters

1671 Abstracts